Preclinical studies have served as the basis for the use of 2DG and other dietary intervention in tandem with chemotherapy and radiation. Intravenous administration of 2DG 5�C10 min prior to focal irradiation caused 50�C60% rates of tumor-free survival in a number of tumor model systems. Furthermore, a number of studies using Akt inhibitors have demonstrated increased radiosensitivity in cells when activation of Akt is reduced, thus providing another mechanism through which the KC may be affecting radiosensitivity in these tumors. There are a few case reports in the literature suggesting that a ketogenic diet may be an effective therapy for the treatment of human brain tumors. These patients were not enrolled in controlled trials and institutions have utilized varying formulations of the KD; VX-809 Abmole New Use for an Old Drug: COX-independent Anti-inflammatory Effects of Sulindac in CF models variations in adherence include restricted and unrestricted approaches as well as differing durations of implementation. A medium chain triglyceride formulation of the ketogenic diet was implemented in 2 pediatric patients diagnosed with advanced stage malignant astrocytomas. The MCTbased formulation of the ketogenic diet utilized by Nebeling et al is composed of 60% MCT oil, 20% protein, 10% carbohydrates, and 10% other dietary fats. The patients tolerated the diet well and experienced notable clinical improvements 4 to 5 years after diagnosis. Both patients underwent radiotherapy prior to the administration of the ketogenic diet and one of the patients also received chemotherapy. Both patients showed a decline in tumor glucose metabolism which resulted in an improved prognosis with greater median survival. More recently, Zuccoli et al reported on the use of a calorically restricted ketogenic diet in a 65 year old woman diagnosed with a multifocal GBM. Two weeks after the beginning of the KD the patient received standard radiation and temozolomide treatment. Tumor regression was seen 2.5 months following diagnosis. Approximately 7 months after beginning the restricted ketogenic diet the patient stopped following the calorically restricted diet and 3 months later the tumor recurred and the patient succumbed approximately 20 months following initial diagnosis. This report demonstrated the tolerability of a reduced MF63 Abmole mPGES-1 in prostate cancer controls stemness and amplifies EGFR-1 driven oncogenicity calorie ketogenic diet in an adult diagnosed with a GBM. In addition, the diet may have inhibited tumor growth as it is unusual for a multifocal GBM to respond to standard therapy alone in 2.5 months. Finally, it is likely that the diet suppressed edema since the patient did not receive steroids during the radiation and chemotherapy treatment and did not appear to require them.